

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6948

Title: Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? A systematic review.

Reviewer code: 02508740

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-11-01 10:04

Date reviewed: 2013-11-12 03:53

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The biologic therapy with Infliximab is one of the most efficient treatment of UC. In that study authors analyzed the role of IFX in reducing the colectomy rate, risk of post-operative morbidity and cost-effectiveness of IFX therapy. The subject of paper is not new, but still actual, according to more possibilities connecting with biological therapy in more medical centres.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6948

Title: Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? A systematic review.

Reviewer code: 00470799

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-11-01 10:04

Date reviewed: 2013-11-20 00:48

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The manuscript by Rizzo et al, provides a comprehensive systematic review on the impact of biologics for the treatment of ulcerative colitis. The authors made a great effort in consolidating the information available up to date, and generating a good overview on how biologics may be considered as a cost-effective strategy for management of moderate to severe UC conditions. the authors provide a well balanced discussion of the the findings from their meta analysis, and properly evaluate the limitations of their work in relation to the limitations of the initial clinical studies where information was published. I recommend this document for consideration for publication in the journal.